|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A06AH01
|
|
gptkbp:CASNumber
|
73360-69-5
|
|
gptkbp:chemicalFormula
|
C21H26NO4
|
|
gptkbp:contraindication
|
known or suspected gastrointestinal obstruction
|
|
gptkbp:developedBy
|
gptkb:Progenics_Pharmaceuticals
|
|
gptkbp:doesNotCross
|
gptkb:blood-brain_barrier
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1970s
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Methylnaltrexone
|
|
gptkbp:indication
|
opioid-induced constipation in patients with advanced illness
opioid-induced constipation in adults with chronic non-cancer pain
|
|
gptkbp:IUPACName
|
(R)-N-(Cyclopropylmethyl)-6,14-endoetheno-7,8-dihydro-14-hydroxy-3-methoxy-17-methylmorphinanium-17-carboxamide
|
|
gptkbp:KEGGID
|
D08209
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:marketedAs
|
gptkb:Salix_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
peripherally-acting mu-opioid receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
356.44 g/mol
|
|
gptkbp:notRecommendedFor
|
treatment of opioid addiction
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1201192
DB06800
4515022
5360491
|
|
gptkbp:relatedTo
|
gptkb:naloxone
gptkb:naltrexone
|
|
gptkbp:routeOfAdministration
|
oral
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
dizziness
flatulence
|
|
gptkbp:synonym
|
gptkb:Relistor
|
|
gptkbp:UNII
|
Q1J8A4J6ZG
|
|
gptkbp:usedFor
|
treatment of opioid-induced constipation
|
|
gptkbp:bfsParent
|
gptkb:Opioids
|
|
gptkbp:bfsLayer
|
7
|